From: Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy
Stage(s) | Classification | n | Survival (month) (mean ± SD) | CA 19-9 (units/ml) (median (range)) | |
---|---|---|---|---|---|
Baseline | After chemotherapy | ||||
III | Good-responder | 11 | 23.5 ± 4.9 | 179.5 (85.7, 371.2) | 25.6 (9.7, 148.2) |
 | Limited-responder | 8 | 7.3 ± 3.2 | 447.4 (50.4, 17,089.3) | 517.3 (19.8, 1388.5) |
IV | Good-responder | 15 | 20.1 ± 8.1 | 1116.8 (112.3, 5229.2) | 250.1 (13.3, 1851.8.4) |
 | Limited-responder | 18 | 6.7 ± 3.8 | 5532.8 (426.0, 64,178.0) | 4642.0 (195.7, 88,904.1) |
III and IV | Good-responder | 26 | 21.6 ± 7.0 | 395.9 (67.1, 4451.9) | 125.3 (9.0, 795.0) |
 | Limited-responder | 26 | 6.9 ± 3.5 | 3164.5 (80.2, 51,831.1) | 1123.9 (26.0, 55,992.8) |